Botox 200 unit vials
Ended Awarded
- Contract number
- SPE2DR26FBYLJ
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,203
Award facts
- Contract value 100% obligated
- $13,203.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $13,203.20 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for 200-unit vials of BOTOX. The award, issued on October 27, 2025, with an ultimate completion date of November 18, 2025, was made without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical supply solutions to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group Inc. serves as a critical supplier within the federal pharmaceutical supply chain, leveraging its established performance across multiple therapeutic categories and product lines to fulfill diverse medical supply needs of military healthcare operations. The company maintains a comprehensive product portfolio that includes branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables. As a prime vendor contractor under the PPV-G GEN V program, which features a 30-month base period with three 30-month option periods extending through December 31, 2036, DMS Pharmaceutical Group is positioned to support recurring pharmaceutical requirements across the global Department of Defense medical system, with a contract ceiling value of $499,999,999.
Quick answers
Who was awarded contract SPE2DR26FBYLJ?
SPE2DR26FBYLJ was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 27, 2025.
How much is contract SPE2DR26FBYLJ worth?
The government has obligated $13,203 on SPE2DR26FBYLJ.
Is contract SPE2DR26FBYLJ an order under another contract?
Yes. SPE2DR26FBYLJ is a delivery order under SPE2DR25D9103, an indefinite delivery contract.
Was contract SPE2DR26FBYLJ competed?
The extent of competition for SPE2DR26FBYLJ was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award